Abstract
Amoxapine is a tricyclic antidepressant (TCA) and used in the treatment of major depressive disorder. It is a norepinephrine and serotonin reuptake inhibitor. A more rapid onset of action is discussed in comparison to other antidepressants. There are notable, especially anticholinergic, side effects such as constipation and paralytic ileus, urinary retention, and ECG changes. Amoxapine is potentially lethal when overdosed.
This is a preview of subscription content, log in via an institution to check access.
References
Apiquian R, Fresan A, Ulloa RE, de la Fuente-Sandoval C, Herrera-Estrella M, Vazquez A, Nicolini H, Kapur S. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology. 2005;30:2236–44.
Ban TA, Wilson WH, McEvoy JP. Amoxapine: a review of literature. Int Pharmacopsychiatry. 1980;15:166–70.
Buckley NA, McManus PR. Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998;18:369–81.
Chaudhry IB, Husain N, Khan S, Badshah S, Deakin B, Kapur S. Amoxapine as an antipsychotic: comparative study versus haloperidol. J Clin Psychopharmacol. 2007;27:575–81.
Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull. 1993;29:175–81.
Drugbank.ca. https://www.drugbank.ca/drugs/DB00543. Accessed 12 Nov 2019.
Fitzgerald PB, Filia S, De Castella A, McBain N, Kapur S, Kulkarni J. Amoxapine in schizophrenia: a negative double-blind controlled trial. J Clin Psychopharmacol. 2004;24:448–50.
Food and Drug Administration (FDA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf. Accessed 16 Dec 2018.
Fruensgaard K, Hansen CE, Korsgaard S, Nymgaard K, Vaag UH. Amoxapine versus amitriptyline in endogenous depression. A double-blind study. Acta Psychiatr Scand. 1979;59:502–8.
Hekimian LJ, Friedhoff AJ, Deever E. A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. J Clin Psychiatry. 1978;39:633–7.
Jue SG, Dawson GW, Brogden RN. Amoxapine: a review of its pharmacology and efficacy in depressed states. Drugs. 1982;24:1–23.
Kapur S, Cho R, Jones C, McKay G, Zipursky RB. Is amoxapine an atypical antipsychotic? Positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biol Psychiatry. 1999;45:1217–20.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102–9.
Kinney JL, Evans RL Jr. Evaluation of amoxapine. Clin Pharm. 1982;1:417–24.
Neuroscience based Nomenclature. http://www.nbn2.com/search#drug/6. Accessed 14 Dec 2018.
Stahl SM. Prescriber’s guide. 6th ed. Cambridge, MA: Cambridge University Press; 2017.
Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;11:249–58.
Uptodate.com. Accessed 14 Dec 2018.
White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol. 2008;4:238–50.
Winek CL, Wahba WW, Rozin L. Amoxapine fatalities: three case studies. Forensic Sci Int. 1984;26:33–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this entry
Cite this entry
Rujescu, D., Röttig, S., Krause, T.J. (2020). Amoxapine and Depressions. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_82-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_82-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine